… Stratification of patients with ATTR-CM is critical for optimal management and treatment;
however, monitoring disease progression is challenging and currently lacks best-practice …

… ATTR amyloidosis … monitoring disease state and detecting disease progression based on
a literature review of expert opinion articles and management guidelines on ATTRv amyloidosis…

… Systemic monitoring of asymptomatic carriers should be considered at least 10 years prior
… For patients with systemic ATTR amyloidosis, TTR amyloid detection and characterisation in …

… light chain amyloidosis (AL) caused by monoclonal immunoglobulin light chains and
transthyretin amyloidosis (ATTR) caused by either mutated or wild-type transthyretin aggregates. …

… We discussed recommendations on monitoring of early signs of ATTRv amyloidosis. …
predictive genetic testing and management of pathogenic TTR gene mutation carriers [4,13]. …

… systems in TTR amyloidosis should also be considered. Nevertheless, monitoring response
… In conclusion Tafamidis is a safe drug easy to manage, for patients and doctors. It is the only …

… transthyretin amyloidosis gene mutation carriers for cardiac involvement, and the ideal method
for monitoring … recent advances in treatment for transthyretin amyloidosis‐CA, including a …

… amyloidosis, such as TTR stabilizers, short interfering RNA (siRNA), and antisense
oligonucleotides (ASOs), early diagnosis and better management … management of ATTR …

… -term monitoring of the changing state of ATTR amyloidosis. Tests … years of transthyretin
familial amyloid polyneuropathy (TTR-… the epidemiology and management patterns for TTR-FAP …

… of TTR amyloid fibrils in different sites, leading to progressive multisystem dysfunction. Citation1
Amyloid … Systematic and regular monitoring of TTR asymptomatic carriers is essential to …